BR112018017144A2 - inibidores de peptídeo de canais de cálcio - Google Patents
inibidores de peptídeo de canais de cálcioInfo
- Publication number
- BR112018017144A2 BR112018017144A2 BR112018017144A BR112018017144A BR112018017144A2 BR 112018017144 A2 BR112018017144 A2 BR 112018017144A2 BR 112018017144 A BR112018017144 A BR 112018017144A BR 112018017144 A BR112018017144 A BR 112018017144A BR 112018017144 A2 BR112018017144 A2 BR 112018017144A2
- Authority
- BR
- Brazil
- Prior art keywords
- calcium channel
- peptide inhibitors
- calcium
- channel peptide
- present
- Prior art date
Links
- 108090000312 Calcium Channels Proteins 0.000 title abstract 3
- 102000003922 Calcium Channels Human genes 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000009460 calcium influx Effects 0.000 abstract 3
- 210000005091 airway smooth muscle Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298204P | 2016-02-22 | 2016-02-22 | |
| PCT/US2017/018840 WO2017147128A1 (en) | 2016-02-22 | 2017-02-22 | Peptide inhibitors of calcium channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018017144A2 true BR112018017144A2 (pt) | 2019-01-15 |
Family
ID=59685595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018017144A BR112018017144A2 (pt) | 2016-02-22 | 2017-02-22 | inibidores de peptídeo de canais de cálcio |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10894811B2 (enExample) |
| EP (1) | EP3419994B1 (enExample) |
| JP (1) | JP2019512216A (enExample) |
| AU (1) | AU2017222450A1 (enExample) |
| BR (1) | BR112018017144A2 (enExample) |
| ES (1) | ES2979122T3 (enExample) |
| IL (1) | IL261265A (enExample) |
| MX (1) | MX2018010132A (enExample) |
| WO (1) | WO2017147128A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018111903A1 (en) * | 2016-12-13 | 2018-06-21 | Spyryx Biociences, Inc. | Saline formulations of splunc1 peptides |
| EP4314010A4 (en) * | 2021-03-22 | 2025-03-05 | The University of North Carolina at Chapel Hill | MODIFIED PEPTIDOMIMETICS AND METHODS OF USE |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| JP2627899B2 (ja) | 1987-08-19 | 1997-07-09 | 株式会社 ビタミン研究所 | 遺伝子封入リポソームの製法 |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| DK0452457T3 (da) | 1989-11-03 | 1998-03-02 | Univ Vanderbilt | Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| JP2001500015A (ja) | 1996-09-06 | 2001-01-09 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法 |
| CA2271325A1 (en) | 1996-11-12 | 1998-05-22 | The Regents Of The University Of California | Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
| DE60101305D1 (de) * | 2000-02-24 | 2004-01-08 | Oxford Glycosciences Uk Ltd | Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten |
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| WO2005056045A1 (en) * | 2003-12-04 | 2005-06-23 | The University Of Iowa Research Foundation | Methods and compositions related to plunc polypeptides |
| DE102004031579B4 (de) * | 2004-06-29 | 2012-12-27 | Forschungsverbund Berlin E.V. | Peptide zur Inhibition der Interaktion von Proteinkinase A und Proteinkinase A-Ankerproteinen, diese umfassendes Nukleinsäuremolekül, Vektor, Wirtszelle, gegen diese gerichtetes Erkennungsmolekül, diese enthaltende pharmazeutische Zusammensetzung, diese enthaltender Kit und deren Verwendung |
| BR112014006535A2 (pt) * | 2011-09-20 | 2017-03-28 | Univ North Carolina Chapel Hill | regulação dos canais de sódio através das proteínas plunc |
-
2017
- 2017-02-22 ES ES17757105T patent/ES2979122T3/es active Active
- 2017-02-22 EP EP17757105.6A patent/EP3419994B1/en active Active
- 2017-02-22 US US16/078,397 patent/US10894811B2/en active Active
- 2017-02-22 JP JP2018544213A patent/JP2019512216A/ja active Pending
- 2017-02-22 WO PCT/US2017/018840 patent/WO2017147128A1/en not_active Ceased
- 2017-02-22 BR BR112018017144A patent/BR112018017144A2/pt not_active IP Right Cessation
- 2017-02-22 AU AU2017222450A patent/AU2017222450A1/en not_active Abandoned
- 2017-02-22 MX MX2018010132A patent/MX2018010132A/es unknown
-
2018
- 2018-08-21 IL IL261265A patent/IL261265A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10894811B2 (en) | 2021-01-19 |
| ES2979122T3 (es) | 2024-09-24 |
| EP3419994B1 (en) | 2024-05-08 |
| EP3419994A1 (en) | 2019-01-02 |
| WO2017147128A1 (en) | 2017-08-31 |
| JP2019512216A (ja) | 2019-05-16 |
| EP3419994C0 (en) | 2024-05-08 |
| US20190062386A1 (en) | 2019-02-28 |
| MX2018010132A (es) | 2019-06-06 |
| IL261265A (en) | 2018-10-31 |
| AU2017222450A1 (en) | 2018-09-27 |
| EP3419994A4 (en) | 2019-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002018A1 (es) | Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582) | |
| BR112022002540A2 (pt) | Materiais e métodos para fragmentos variáveis de cadeia única aprimorados | |
| BR112018013995A2 (pt) | terapia de combinação de vírus oncolítico e inibidor de ponto de verificação | |
| BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
| CL2018001897A1 (es) | Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509) | |
| Réus et al. | Glutamatergic NMDA receptor as therapeutic target for depression | |
| UA120060C2 (uk) | Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування | |
| BR112015023207A8 (pt) | composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase. | |
| CR20170011A (es) | Compuestos de heteroarilo para la inhibición de cinasa | |
| BR112018008358A2 (pt) | ?composições e métodos para terapia relacionada à microbiota fecal? | |
| BR112017009159A2 (pt) | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| BR112017020054A2 (pt) | anticorpos para icos | |
| MX2020012064A (es) | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. | |
| BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
| BR112016000809A2 (pt) | Método para tratar infecção, sepsia e lesão | |
| BR112017023646A2 (pt) | proteínas agonistas de receptor de cd40 de cadeia simples | |
| PH12016500302A1 (en) | Compositions and method for treating complement-associated conditions | |
| BR112017028287A2 (pt) | Combinação do inibidor hdac e anticorpido anti-pd- l1 para o tratamento do câncer | |
| BR112018072723A2 (pt) | composição, e, métodos para tratar uma doença em um sujeito e para aumentar uma resposta imunológica em um sujeito | |
| MX2018002067A (es) | Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr. | |
| BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
| BR112018008799A2 (pt) | método de prognóstico | |
| BR112014026160A2 (pt) | métodos para tratar intolerância à lactose | |
| BR112017022653A2 (pt) | ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15V | Prolongation of time limit allowed |
Free format text: TENDO EM VISTA O COMUNICADO NA RPI 2564 DE 27/02/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2658 DE 14-12-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |